BioStem Technologies reported second quarter 2026 net revenue of $7.9 million, a 29% sequential increase from the first quarter's $6.1 million, driven by Neox and Clarix product sales. The company raised its full-year 2026 revenue guidance to a range of $26 million to $29 million, up from the previous upper bound of $25 million. GAAP net loss widened to $9.0 million, or $0.52 per share, compared to a near-breakeven result in the prior year period, as operating expenses rose to $13.2 million due to commercial expansion. BioStem also completed a $2.5 million private placement with its first institutional investor and uplisted its common stock to the Nasdaq Capital Market on August 7, 2026. The company operates in the regenerative medicine industry, developing, manufacturing, and commercializing perinatal tissue allograft products.